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maintaining self-renewal and leading to
a poor prognosis. Notably, combined
expression of Myb, Cbx5, and Hmgb3
expression was reduced following condi-
tional inactivation of the MLL-ENL onco-
protein commensurate with loss of LSC
clonogenic activity and induction of differ-
entiation into macrophages. Similarly,
Myb knockdown decreased LSC fre-
quency and induced LSC differentiation.
However, coincident expression of all
three genes was required to induce the
serial replating capacity characteristic of
LSCs. Finally, although previous reports
indicated that LSCs may be quiescent,
this study demonstrates that the AML
bone marrow population containing the
highest frequency of cycling cells also
harbors the highest frequency of LSCs.
While this does not obviate the possibility
that some leukemias are generated by
primarily quiescent LSCs, MLL-driven
mouse myeloid leukemias appear to be
propagated bymetabolically active, prolif-
erating LSCs.
By dissecting the molecular pathways
involved in LSC generation in response
to MLL deregulation, Somervaille and
colleagues have significantly advanced
the field of cancer stem cell research by
linking the extent of subversion of embry-
onic transcriptional programs involved in
regulating self-renewal and the frequency
of LSCs. They have provided important
insights into the genetic factors regulating
the frequency of LSCs as well as the most
critical pathways to target in clinical trials.
This seminal work is likely to have far-
reaching implications for the design of
novel therapies targeting cancer stem
cells in other malignancies.
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In a recent issue of Chemistry & Biology, Bone et al. (2009) employed a chemical biology approach to probe
the role of glycogen synthase kinase-3 (GSK-3), a key regulator of pluripotentiality, providing new insights
and tools for modulating this process.Themultifunctional serine-threoninekinase,
glycogen synthase kinase-3 (GSK-3),
has recently been identified as a critical
modulator of embryonic stem cell (ESC)
properties, largely based on experiments
using selective GSK-3 inhibitors. Due to
the use of various cell lines (from mouse
and human), inconsistency in cell culture
conditions, and experimental assays, as
well as different small molecule inhibitors
of GSK-3, the precise role that GSK-3 plays
in ESCs has been somewhat ambiguous.
Bone et al. used a macrocyclic bisindolyl-98 Cell Stem Cell 4, February 6, 2009 ª2009maleimide compound 1i, previously identi-
fied as a selective small-molecule ATP-
competitive inhibitor of GSK-3, and con-
trasted its effects with two structurally
distinct GSK-3 inhibitors that have previ-
ously been reported: 6-bromoindirubin-3-
oxime (BIO) and TWS119. BIO was initially
demonstrated to be capable of maintaining
the pluripotency of both mouse and human
ESCs through a mechanism dependent
upon activation of Wnt/b-catenin signaling
(Sato et al., 2004). Subsequently, it was re-
ported that sustained GSK-3 inhibition orElsevier Inc.canonical Wnt activation in both mouse
and human ESCs promotes their differenti-
ation into multipotent mesendodermal
progenitors or their differentiated progeny
(Bakre et al., 2007; Dravid et al., 2005).
While most studies with GSK-3 inhibitors
and ESCs support a role for GSK-3 in the
maintenance of undifferentiated pluripotent
cells, the GSK-3 inhibitor TWS119 was
reported to induce neuronal differentiation
of ESCs (Ding et al., 2003).
The standardmethodused topropagate
mouse ESCs (mESCs) is in rich medium,
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Previewscontaining high levels of fetal
bovine serum, supplemented
with the cytokine leukemia
inhibitory factor (LIF), although
serum-free medium contain-
ing only LIF and bonemorpho-
genetic protein-4 (BMP4) is
sufficient to maintain these
cells in a self-renewing, undif-
ferentiated state. The pro-
posedmode of action of these
extrinsic factors is thatLIFacti-
vation of Stat3 enhances ESC
self-renewal, while BMP4,
acting through Smad-medi-




(Ying et al., 2003). In vitro
GSK-3 activity assays indi-
cated that 1i inhibits GSK-3
present in mESC lysates with
an IC50 of 250 nM, some 5-
fold higher than that obtained
with BIO. Bone et al. (2009)
then sought to determine if 1i
was capable of enhancing the
propagation of undifferenti-
ated mESCs as previously
reported for BIO. Undifferenti-
ated ESCs express high levels
of alkaline phosphatase (AP),
which is easily detected
through histochemical staining
for enzymatic activity. The
authors used AP staining as a surrogate
marker for undifferentiated mESC colonies
in a clonal assay in which limiting dilutions
of ESCs were plated out in serum and LIF
for 5 days. Colonies present after this 5
day period were scored based on their AP
levels. The inhibitors TWS119 (2 mM), BIO
(0.5 mM), or 1i (5 mM) each elevated the
number of undifferentiated ESC clones
scored in this manner and, thus, were
interpreted to enhance ESC self-renewal.
One of the best-characterized GSK-3
substrates is the transcriptional coactivator
b-catenin, a mediator of canonical Wnt
signaling. GSK-3-mediated phosphoryla-
tion of b-catenin promotes its proteasomal
degradation; inhibition of GSK-3 therefore
results in b-catenin accumulation in the
cytoplasm and its subsequent transloca-
tion to the nucleus where it activates T cell
factor/lymphoid enhancer-binding factor
(TCF/LEF)-mediated transcription of target
genes. To assess the relative extent of
GSK-3 inhibition obtained by 1i, BIO, or
TWS119 in mESCs, Bone et al., monitored
the stabilization of b-catenin and the
subsequent activation of the b-catenin/
TCF reporter constructs as indicators of
GSK-3 inhibition in intact cells. Theminimal
concentrations of BIO and 1i that resulted
in detectable b-catenin dephosphorylation
on GSK-3 target residues after a 30 min
incubation also enhanced TCF-reporter
activity to a similar extent and correlated
with the concentrations of each inhibitor
that enhancedmaintenance of AP-positive
mESC colonies. In contrast, the inhibitor
TWS119, increased the number of AP-
positive mESC colonies scored at 5 days
at 2 mM, yet only modestly elevated TCF-
reporter activity at this dose, suggesting
that it might have other targets in mESCs
that may be responsible for its distinct
effects, such as neuronal differentiation.
Bone et al. went on to synthesize 48
derivatives of 1i with the goal of enhancing
the potency of the lead com-
pound. The new compounds
were screened based on the
clonal mESC self-renewal
assay described above, and
12 were found to enhance
maintenance of undifferenti-
atedmESCwith potency equal
to or better than 1i. A more
detailed characterization of
the twelve most effective
compounds revealed a direct
correlation between a com-
pound’s potency for GSK-3
inhibition and ability to
enhance the retention of undif-
ferentiated mESC colonies.
The three most potent deriva-
tives (1l, 1m, and 1o) were
approximately 103 more
potent than the lead com-
pound, 1i. The extent to which
GSK-3 inhibitors 1i, 1l, 1m,
1o, BIO, and TWS119 exerted
off-targeteffectson threepath-
ways regulating mESC self-
renewal—the Stat3, PI3K/Akt,
and MAPK—pathways, was
tested. While 1i, 1l, 1m, and
1o had no apparent affect on
these signaling pathways,
both BIO and TWS119 caused
significant suppression of
Erk1/2 signaling and Stat3
phosphorylation. All of the
GSK-3 inhibitors tested by
Bone et al. enhancedmaintenance of undif-
ferentiated mESCs only in the presence of
LIF and serum.
While theBoneetal. analysis strengthens
the notion that small molecule inhibitors of
GSK-3 potentiate self-renewal of pluripo-
tentmESCs, themechanism throughwhich
GSK-3 inhibition imparts this effect is still
unclear. That GSK-3 inhibition in and of it-
self enhances self-renewal of mESCS is
not surprising given that GSK-3 nullizygous
ESCs display this phenotype (Doble et al.,
2007). Still, the newly synthesized, highly
specific, and potent 1i-basedGSK-3 inhib-
itor series should prove very useful
for further dissection of GSK-3’s role in
stem cell biology. GSK-3 has the unique
property of regulating multiple signal-
ing pathways, including Wnt/b-catenin,
Hedgehog,Notch, andPI3Kpathways (Fig-
ure1), andalsodirectly regulatesnumerous
transcription factors, including c-Myc,
which has been directly linked to mESC
Figure 1. GSK Signaling Cascades in ESCs
GSK-3 plays a central role in the Wnt, Hedgehog, Notch, and PI3K signaling
pathways, serving to negatively regulate the transcription factors b-catenin/
TCF, Gli2/3, and NICD, as well as metabolic enzymes involved in glycogen
and protein synthesis. Inhibition of GSK-3 in ESCs, in the presence of the cyto-
kine LIF, enhances their self-renewal and prevents downregulation of core plu-
ripotency factors, Oct-4 and Nanog, through an unknown mechanism. There
are likely GSK-3 target molecules, yet to be identified, that are involved in its
regulation of stem cell properties, which may be cytosolic or nuclear (as de-
picted). The transcription factor c-Myc, which has been linked to ESC pluripo-
tency, aswell as iPSCgeneration, is negatively regulated byGSK-3. Prolonged
activation of Wnt/b-catenin signaling has been linked to mesendoderm differ-
entiation. GSK-3 nullizygous mouse ESCs are refractory to neurectodermal
differentiation, potentially due to hyperactivated Wnt signaling. Although
controversial, a role for b-catenin, perhaps independent of TCF, has been sug-
gested to enhance ESC pluripotency under some conditions. b-cat, b-catenin;
BMP, bonemorphogenetic protein; Hh, hedgehog; GSK-3, glycogen synthase
kinase-3; Id, inhibitor of differentiation; IGF, insulin-like growth factor; LIF,
leukemia inhibitory factor; NICD, Notch intracellular domain; PI3K, phosphoi-
nositide 3-kinase; PKB, protein kinase B (also known as Akt).
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Previewsself-renewal and induced pluripotent stem
cell (iPSC) generation. There is accumu-
latingevidence that thePI3Kpathwayplays
a role in the regulation of pluripotency in
mESCs and human ESCs (Welham et al.,
2007). The precise mechanism(s) through
which PI3K signaling regulate ESC self-
renewal and pluripotency is still unclear,
but regulation of Nanog transcript levels
plays at least a partial role. GSK-3 has
been implicated in the cascade involving
PI3K and Nanog, although the relevant,
direct GSK-3 substrates remain unknown.
Further studies remain to be completed
beforeGSK-3 inhibition-dependentb-cate-
nin stabilization canbe excluded fromplay-
ing a role in ESC self-renewal, especially
given recent data suggesting that TCF3 is
a component of the core transcription
factors regulating ESC pluripotency (Cole
et al., 2008). Inhibition of GSK-3, combined
with inhibition of FGF-mediated MAPK
signaling, hasbeen reported tobesufficient
for maintenance of mESCs in serum-free
culture conditions (Ying et al., 2008). Under
these conditions, inhibition of GSK-3 has
been proposed to act primarily via promo-The River of Stem
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stem cell and transient amplifying
regulated to form different number
Ectodermalorgansare fascinatingbecause
they can undergo either continual turn
over or episodic regeneration and yet are
able to regulate their size, topology, and
ratio of differentiated cell types, depend-
ing on physiological needs or in response
to injury. Understanding this mechanism
is central to the progress of regenerative
medicine. In the current concept (Potten,
1981), the system is regulated by the equi-
librium among three major cell groups:
stem cells, transit-amplifying (TA) cells,
100 Cell Stem Cell 4, February 6, 2009 ª20tion of cell viability. The study by Bone
et al., in which GSK-3 inhibition retains an
effect in the presence of serum and LIF,
suggests thatGSK-3 inhibitionexerts direct
effects on ESC self-renewal machinery in
addition to any function as a survival factor.
The development of defined chemical
cocktails that maintain stem cell pluripo-
tency would simplify expansion of ESC
and iPSCs by overcoming the current
need for animal sera and protein factors. A
chemical genetics approach, such as that
used by Bone et al., uses the phenotype
of a classical genetic modification (e.g.,
GSK-3 DKO) as the ‘‘gold standard’’ that
is tobemimicked throughchemicalmeans.
This powerful strategy allows for the devel-
opment of ‘‘clean’’ chemical tools with
minimal undesired off-target effects, which
will be invaluable for future stem cell appli-
cations.
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Using long-term label retention, Cotsar-
elis et al. (1990) discovered slow cycling
cells within the hair bulge. These bulge
cells were found to give rise to future hair
follicles and considered to be the main
sites of hair stemcells.Matrix at the follicle
base contains rapid proliferating TA cells.
These cells generate different differenti-
ated cell types of hair filaments. Based on
morphology, a second population of cells
surrounding the dermal papilla, called the
hair germ, was identified and thought to
